Crispr Therapeutics Ag (NQ: CRSP )
62.59 -0.19 (-0.30%) Streaming Delayed Price Updated: 4:00 PM EDT, Jun 8, 2023 Add to My Watchlist
All News about Crispr Therapeutics Ag
Benzinga's Top Ratings Upgrades, Downgrades For August 9, 2022
August 09, 2022
MarketBeat: Week in Review 8/1 - 8/5
August 06, 2022
The hot jobs report is dispelling any notion that interest rates will level off. But the market moves on and here are some of the stocks and stories to follow.
Topics Economy Electric Vehicles
Exposures Electric Vehicles Interest Rates
Cathie Wood Sheds $5M In CRISPR Therapeutics, Scoops Up These Biotech Stocks Instead
August 05, 2022
Cathie Wood-led Ark Investment Management on Thursday sold 70,723 shares of gene editing company CRISPR Therapeutics AG (NASDAQ: CRSP), valued at over $5.58 million, via its flagship fund.
Evercore ISI Group downgraded its rating of CRISPR Therapeutics (NASDAQ:CRSP) to In-Line with a price target of $60.00, changing its price target from $66.00 to $60.00. Shares of CRISPR Therapeutics...
Chardan Capital Maintains Buy Rating for CRISPR Therapeutics: Here's What You Need To Know
June 22, 2022
Chardan Capital has decided to maintain its Buy rating of CRISPR Therapeutics (NASDAQ:CRSP) and lower its price target from $168.00 to $164.00. Shares of CRISPR Therapeutics are trading down 8.24% over...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following